These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28092042)

  • 1. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
    Asai A; Takakuma K
    Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
    Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
    PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
    Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
    Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and Purification of Soluble STAT5b/STAT3 Proteins for SH2 Domain Binding Assay.
    Asai A; Takakuma K
    Methods Mol Biol; 2017; 1555():163-172. PubMed ID: 28092032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization.
    Müller J; Schust J; Berg T
    Anal Biochem; 2008 Apr; 375(2):249-54. PubMed ID: 18258175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
    Resetca D; Haftchenary S; Gunning PT; Wilson DJ
    J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
    Shao S; Yu R; Yu Y; Li Y
    J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
    Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
    PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP Inhibits the Transcription Factor STAT5b.
    Berg A; Sperl B; Berg T
    Chembiochem; 2019 Sep; 20(17):2227-2231. PubMed ID: 30985989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
    Furtek SL; Matheson CJ; Backos DS; Reigan P
    Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening.
    Hao W; Hu Y; Niu C; Huang X; Chang CP; Gibbons J; Xu J
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4988-92. PubMed ID: 18768317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
    Furtek SL; Backos DS; Matheson CJ; Reigan P
    ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
    Yu W; Xiao H; Lin J; Li C
    J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders.
    Gunning PT; Glenn MP; Siddiquee KA; Katt WP; Masson E; Sebti SM; Turkson J; Hamilton AD
    Chembiochem; 2008 Nov; 9(17):2800-3. PubMed ID: 19006150
    [No Abstract]   [Full Text] [Related]  

  • 16. An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures".
    Gianti E; Zauhar RJ
    J Comput Aided Mol Des; 2015 May; 29(5):451-70. PubMed ID: 25752764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of a high-throughput fluorescence polarization assay for STAT5B DNA binding domain-targeting inhibitors.
    Manaswiyoungkul P; Erdogan F; Olaoye OO; Cabral AD; de Araujo ED; Gunning PT
    J Pharm Biomed Anal; 2020 May; 184():113182. PubMed ID: 32113119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation.
    Namanja AT; Wang J; Buettner R; Colson L; Chen Y
    J Mol Biol; 2016 Feb; 428(3):579-589. PubMed ID: 26774853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains.
    de Araujo ED; Manaswiyoungkul P; Israelian J; Park J; Yuen K; Farhangi S; Berger-Becvar A; Abu-Jazar L; Gunning PT
    J Pharm Biomed Anal; 2017 Sep; 143():159-167. PubMed ID: 28600954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a small-molecule inhibitor of STAT3 by ligand-based pharmacophore screening.
    Leung KH; Liu LJ; Lin S; Lu L; Zhong HJ; Susanti D; Rao W; Wang M; Che WI; Chan DS; Leung CH; Chan PW; Ma DL
    Methods; 2015 Jan; 71():38-43. PubMed ID: 25160651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.